The FDA has approved United Therapeutics’ Unituxin (dinutuximab) to treat pediatric patients with high-risk cases of neuroblastoma. And the regulatory win comes with a priority review vouch that may well be worth tens of millions of dollars.

…read more

Source: United Therapeutics wins FDA OK for rare kids’ cancer drug, plus a priority review voucher


0 No comments